Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   All Outcomes       

Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing

Miranda et al., Environmental and Molecular Mutagenesis, doi:10.1002/em.22510
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro genotoxocity study of molnupiravir showing dose dependent increased genome-wide mutation frequencies with mouse lymphoma L5178Y and human lymphoblastoid TK6 cells.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-14. Multiple analyses have identified variants potentially created by molnupiravir15-19.
Miranda et al., 1 Oct 2022, peer-reviewed, 4 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperMolnupiravirAll
DOI record: { "DOI": "10.1002/em.22510", "ISSN": [ "0893-6692", "1098-2280" ], "URL": "http://dx.doi.org/10.1002/em.22510", "alternative-id": [ "10.1002/em.22510" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2022-06-14" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 1, "value": "2022-09-28" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 2, "value": "2022-10-01" } ], "author": [ { "affiliation": [ { "name": "Division of Genetic and Molecular Toxicology National Center for Toxicological Research, U.S. Food and Drug Administration Jefferson Arkansas USA" } ], "family": "Miranda", "given": "Jaime A.", "sequence": "first" }, { "affiliation": [ { "name": "Division of Genetic and Molecular Toxicology National Center for Toxicological Research, U.S. Food and Drug Administration Jefferson Arkansas USA" } ], "family": "McKinzie", "given": "Page B.", "sequence": "additional" }, { "affiliation": [ { "name": "Division of Genetic and Molecular Toxicology National Center for Toxicological Research, U.S. Food and Drug Administration Jefferson Arkansas USA" } ], "family": "Dobrovolsky", "given": "Vasily N.", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-0518-2096", "affiliation": [ { "name": "Division of Genetic and Molecular Toxicology National Center for Toxicological Research, U.S. Food and Drug Administration Jefferson Arkansas USA" } ], "authenticated-orcid": false, "family": "Revollo", "given": "Javier R.", "sequence": "additional" } ], "container-title": "Environmental and Molecular Mutagenesis", "container-title-short": "Environ and Mol Mutagen", "content-domain": { "crossmark-restriction": true, "domain": [ "onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2022, 10, 1 ] ], "date-time": "2022-10-01T08:20:27Z", "timestamp": 1664612427000 }, "deposited": { "date-parts": [ [ 2022, 10, 1 ] ], "date-time": "2022-10-01T08:20:27Z", "timestamp": 1664612427000 }, "indexed": { "date-parts": [ [ 2022, 10, 2 ] ], "date-time": "2022-10-02T04:45:29Z", "timestamp": 1664685929956 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2022, 10 ] ] }, "language": "en", "license": [ { "URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 10, 1 ] ], "date-time": "2022-10-01T00:00:00Z", "timestamp": 1664582400000 } }, { "URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 10, 1 ] ], "date-time": "2022-10-01T00:00:00Z", "timestamp": 1664582400000 } } ], "link": [ { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/em.22510", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/em.22510", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "prefix": "10.1002", "published": { "date-parts": [ [ 2022, 10 ] ] }, "published-online": { "date-parts": [ [ 2022, 10 ] ] }, "publisher": "Wiley", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1002/em.22510" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Health, Toxicology and Mutagenesis", "Genetics (clinical)", "Epidemiology" ], "subtitle": [], "title": "Evaluation of the mutagenic effects of Molnupiravir and\n <scp>N4</scp>\n ‐hydroxycytidine in bacterial and mammalian cells by\n <scp>HiFi</scp>\n sequencing", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1002/crossmark_policy" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit